News | December 28, 2023
Elpiscience and Astellas collaborate for novel bispecific macrophage engager
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Subscribe To Our Newsletter & Stay Updated
